Follicular Mixed Cell Lymphoma is a type of non-Hodgkin lymphoma (NHL), which is a cancer that affects the lymphatic system. It is characterized by the clonal expansion of B-cell lymphocytes within the lymph nodes and other lymphoid tissues. This specific subtype of NHL derives its name from its composition of different cell types within the tumor.
The term "follicular" refers to the neoplastic growth pattern resembling normal lymph node structures known as germinal centers. These germinal centers play a crucial role in the production of lymphocytes. However, in follicular mixed cell lymphoma, this process becomes abnormal and results in the formation of a tumor.
The phrase "mixed cell" indicates that the tumor comprises a combination of different cell types, including centrocytes, centroblasts, and small lymphocytes. These cell types contribute to the heterogeneous appearance of the tumor and can be identified through microscopic examination.
Follicular mixed cell lymphoma is typically graded according to the number and presence of centroblasts in the tumor. A higher grade signifies a higher number of centroblasts and is associated with a poorer prognosis.
Symptoms of follicular mixed cell lymphoma may include painless swollen lymph nodes, fever, weight loss, night sweats, and general fatigue. Treatment options may vary depending on the stage and grade of the cancer but often include a combination of chemotherapy, immunotherapy, radiation therapy, and targeted therapies such as monoclonal antibodies.
Overall, follicular mixed cell lymphoma represents a specific subtype of non-Hodgkin lymphoma characterized by the presence of a mixed cell population within the tumor, resembling the normal structure and composition of lymph nodes.
